Navigation Links
DURECT Announces ELADUR® (TRANSDUR®-Bupivacaine) Phase II Study Results in Chronic Low Back Pain
Date:4/11/2011

CUPERTINO, Calif., April 11, 2011 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today top-line results from a Phase II clinical trial in chronic low back pain for ELADUR® (TRANSDUR®-Bupivacaine), DURECT's proprietary investigational transdermal bupivacaine pain patch.  This study was conducted by DURECT's collaborator, King Pharmaceuticals, which is now owned by Pfizer (NYSE: PFE).  In this study of 263 patients suffering from chronic low back pain, the primary efficacy endpoint of demonstrating a positive treatment difference for the mean change in pain intensity scores from baseline to the mean of weeks 11 and 12 between ELADUR as compared to placebo was not met.  Complete data analysis is on-going.

(Logo:  http://photos.prnewswire.com/prnh/20020717/DRRXLOGO)

ELADUR is an investigational transdermal drug patch intended to deliver bupivacaine for up to 3 days from a single application.  Bupivacaine, the active agent in ELADUR, is a potent, FDA-approved long-acting local anesthetic used in regional anesthesia for local tissue infiltration, nerve block, and epidural and intrathecal anesthesia.  ELADUR demonstrated a positive efficacy trend in a Phase 2a study for post-herpetic neuralgia (PHN); a poster describing this study was presented at the 27th Annual Scientific Meeting of the American Pain Society on May 8, 2008 and is accessible on DURECT's website (http://www.durect.com/wt/durect/page_name/Publications).

"Demonstrating efficacy against placebo in a chronic low back pain trial is challenging for any topical locally-acting product," stated James E. Brown, DVM, President and CEO of DURECT.  "We and Pfizer are continuing to analyze this most recent study and will work
'/>"/>

SOURCE DURECT Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. DURECT to Present at Cowen and Company Health Care Conference
2. DURECT Corporation Invites You to Join its Fourth Quarter 2010 Earnings Conference Call
3. DURECT Reports Data From European Phase IIb Shoulder Study of POSIDUR™ (SABER™-Bupivacaine) and Amendment of the Nycomed Agreement
4. DURECT Announces Launch of First FDA Approved SABER™-Injectable Peptide Product
5. DURECT to Present at the BIO CEO & Investor Conference
6. DURECT to Present at the Credit Suisse 2010 Healthcare Conference
7. DURECT Corporation Announces Third Quarter 2010 Financial Results
8. DURECT Corporation Invites You to Join Its Second Quarter 2010 Earnings Conference Call
9. DURECT to Present at the BMO Capital Markets Focus on Healthcare Conference
10. DURECT Corporation Secures $50 Million Committed Equity Financing Facility
11. DURECT Reports Data From European Phase IIb Hysterectomy Study of POSIDUR(TM) (SABER(TM)-Bupivacaine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... CHENGDU, China , Jan. 23, 2015 Tianyin ... pharmaceutical company that specializes in the development and sale ... branded generics and active pharmaceutical ingredients (API) today announced ... Facility (JCM) API operation. 1. Following the ...
(Date:1/22/2015)... /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), ... for cardiovascular disease and overall health is pleased to provide ... and its outlook for 2015 from the CEO, Mr. ... We would like to take this opportunity to share with ...
(Date:1/22/2015)... DUBLIN , Jan. 22, 2015 Research and Markets ... of the "Infectious Disease Diagnostics Market by Product, ... report to their offering. , The ... CAGR of 7.9% to reach $18,156.2 million by 2019 ...
Breaking Medicine Technology:TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 2Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 3
...  Aria Diagnostics, a molecular diagnostics company, today announced ... examines the accuracy of its non-invasive prenatal test ... Down syndrome) and Trisomy 18 (associated with Edwards ... with a proprietary algorithm to assess individualized risk ...
... Health Resource, Inc. (OTCBB: CHRI.OB News), announced today that ... of Gastrodia valued at 67.5 Million RMB or approximately ... Valley Pharm Corp and Sichuan Zhiyuanguanghe Pharm Corp and ... of Gastrodia from January 1, 2012 to December 31, 2012. ...
Cached Medicine Technology:Aria Announces Publication of Independent Study in the American Journal of Obstetrics & Gynecology Using Aria's Technology 2China Health Resource Signs Two New Agreements for the Sale of Gastrodia Valued at $10 Million USD (Corrected*) 2China Health Resource Signs Two New Agreements for the Sale of Gastrodia Valued at $10 Million USD (Corrected*) 3
(Date:1/22/2015)... (PRWEB) January 22, 2015 Yesterday, ... Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were honored ... leadership in advancing biotechnology, biomedical science, medical device ... Olsen each received the “2014 Life Sciences Champion” ...
(Date:1/22/2015)... Four years since the release of their debut recording Love ... of Avasa & Matthew Love – the duo are pleased to ... through White Swan Records on February 24, 2015. , THE ROAD ... available to all of us to walk out of the mire ...
(Date:1/22/2015)... As interest in the value of spiritual support as ... Rev. Eric J. Hall , president and CEO of the ... the keynote speaker on January 27 at an international summit ... The conference, “Hope and Resilience: Innovative and Interdisciplinary Spiritual Care,” ...
(Date:1/22/2015)... 2015 Lower-Auto-Insurance.com has released a new blog post ... car for reducing the costs of an auto insurance policy ... able to get lower prices for their vehicle insurance policies. The ... in determining policy costs. Because of this, drivers should always ...
(Date:12/26/2014)... Dallas, TX (PRWEB) December 26, 2014 The ... covered in this report. In 2013, GlobalData’s forecast estimates that ... the largest CRC market due to the high incidence of ... compared with the 5EU, Japan, and China. Increased sales of ...
Breaking Medicine News(10 mins):Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 3Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 4
... , FAIRFIELD, N.J., Sept. 22 ... today at the Transcatheter Cardiovascular Therapeutics (TCT) convention in San ... cleared the company,s MEGA(TM) 8Fr. 50cc intra-aortic balloon (IAB) ... 8Fr. shaft, the MEGA has a smaller insertion point than ...
... of the H1N1 influenza pandemic could present a host ... advance, according to the University of Toronto Joint Centre ... discussion. Topics include duty of health care workers ... on individual freedoms and privacy and their responsibilities administering ...
... , DETROIT, Sept. 23 Caraco ... on September 20, 2009, Georges Ugeux resigned as a director of ... the Board. Mr. Ugeux was the chairman of the independent committee. ... indicated that he had disagreements with the majority shareholder and senior ...
... , , Former Vermont ... , BURLINGTON, Vt., Sept. 23 -- Governor Howard Dean will ... to discuss health care reform and sign copies of his new book, ... Dean will appear at the Philadelphia Free Library for a ...
... NEW YORK, Sept. 23 The Michael J. Fox Foundation ... translate neurotrophic factor advances from pre-clinical and early-phase clinical work ... will be awarded under a new Directed LEAPS (Linked ... , The Foundation,s intention is to identify and ...
... SCOTTSDALE, Ariz., Sept. 23 Seventh and eighth graders ... experienced firsthand some of the challenges that come with aging. ... the not-for-profit SCAN Health Plan Arizona, the students participated in ... the physical challenges facing seniors. , , ...
Cached Medicine News:Health News:MAQUET Cardiovascular Receives FDA Clearance for MEGA(TM), the World's First 8Fr. 50cc Intra-Aortic Balloon Catheter 2Health News:MAQUET Cardiovascular Receives FDA Clearance for MEGA(TM), the World's First 8Fr. 50cc Intra-Aortic Balloon Catheter 3Health News:Medical ethics experts identify, address key issues in H1N1 pandemic 2Health News:Medical ethics experts identify, address key issues in H1N1 pandemic 3Health News:Medical ethics experts identify, address key issues in H1N1 pandemic 4Health News:Medical ethics experts identify, address key issues in H1N1 pandemic 5Health News:Medical ethics experts identify, address key issues in H1N1 pandemic 6Health News:Medical ethics experts identify, address key issues in H1N1 pandemic 7Health News:Medical ethics experts identify, address key issues in H1N1 pandemic 8Health News:Medical ethics experts identify, address key issues in H1N1 pandemic 9Health News:Caraco Pharmaceutical Laboratories, Ltd. Announces Resignation of Georges Ugeux from Board of Directors 2Health News:Caraco Pharmaceutical Laboratories, Ltd. Announces Resignation of Georges Ugeux from Board of Directors 3Health News:Michael J. Fox Foundation Commits Up to $5 Million to Help Advance Neurotrophic Factors 'From Promise to Reality' As Parkinson's Treatment 2Health News:Twelve Going on 70: SCAN Health Plan Arizona Helps 7th and 8th Graders Understand Aging With Senior Sensitivity Training 2
Full Handle Laseredge Stab Blade Knife, 15 blade. Blade tip dimension: 11.1 mm x 1.5 mm x 5.7 mm....
18 gauge straight. Fine tip. Lightweight design offers precise hemostasis. Pencil design minimizes tissue trauma and induced astigmatism. Knurled handle provides a sure grip and better manipulation....
Set consist of two 27 gauge, stainless steel probes with blunt tips. Probes are 11.5 cm (4.5 inches) long with 30.5 cm (12 inches) of flexible tubing (O.D. - 0.60 mm, I.D. - 0.30 mm) attached onto th...
Straight, soft flexible tip allows atraumatic entry through a retinal tear or hole for aspiration of subretinal fluids. 20 gauge x 25 mm cannula attached to 25 gauge x 6 mm tip with 13 mm flexible tu...
Medicine Products: